SHIM
JBIO

Stone House Investment Management’s Jade Biosciences JBIO Stock Holding History

Stone House Investment Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112 Buy
+8
New +$116 ﹤0.01% 1002

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Stone House Investment Management's JBIO Position: Q1 2026 in Review

Stone House Investment Management opened a new position in Jade Biosciences (JBIO) in Q1 2026: 8 shares worth $112. The stake represents ﹤0.01% of the portfolio and ranks #1002 among its holdings.

120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • Stone House Investment Management held 8 shares of Jade Biosciences worth $112 as of Q1 2026.
  • Jade Biosciences was a new Stone House Investment Management position in Q1 2026.
  • Jade Biosciences made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #1002 holding.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.